Title: Challenges of Comprehensive Genomic Profiling, Immunotherapy and the Liquid Biopsy to Inform Treatment Decisions for Patients with Cancer

Philip J. Stephens, PhD
Chief Scientific Officer
Vice president of Cancer Genomics
Foundation Medicine, Inc. USA

Speaker

Hiroyuki Mano, MD, PhD
Professor, Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Japan

Chairman

Dr. Philip J. Stephens

Profile

Dr. Stephens studied at Oxford University in the United Kingdom, where he received his Ph.D. Now, as vice president of Cancer Genomics, Dr. Stephens leads research and development at Foundation Medicine. Dr. Stephens is a world-renowned expert in next generation sequencing and cancer genome analysis and has authored numerous publications in high-profile, peer-reviewed journals. Since joining Foundation Medicine in early 2011, Dr. Stephens has overseen the development of FoundationOne™, a comprehensive next generation sequencing diagnostic assay that accurately profiles the entire coding sequence of over 200 cancer-related genes in the CLIA setting. Prior to joining Foundation Medicine, he held various senior research positions during his 11-year tenure with the Cancer Genome Project at the Wellcome Trust Sanger Institute in the UK. During this time, Dr. Stephens was a member of the team that sequenced the

first two comprehensive melanoma and lung cancer genomes, and was co-lead author in the discovery of BRAF in melanoma, ERBB2 in lung cancer, and identified chromothripsis as a novel oncogenic mechanism.

Recent Publications

Joshi M, Vasekar M, Grivas P, Emamekhoo H, Hsu J, Miller VA, **Stephens PJ**, Ali SM, Ross JS, Zhu J, Warrick J, Drabick JJ, Holder SL, Kaag M, Li M, Pal SK. Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. *Oncotarget.* 2016 May 18**.**

Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, **Stephens PJ.** Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. *Oncology***.** 2016 May 21.

Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, **Stephens PJ**, Ross JS. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. *Oncologist*. 2016 May 5.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, **Stephens PJ**, Miller VA, Ali SM, Lovly CM. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. *Cancer Discov.* 2016 Apr 21.

Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, Lee J, Kim KM, Gill AJ, Wang K, Gowen K, Sun J, Miller VA, **Stephens PJ**, Ali SM, Ross JS, Safran H. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. *Clin Cancer Res*. 2016 Mar 1.

Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki J, Elvin JA, Wollner M, Dvir A, Soussan-Gutman L, Bordoni R, Peled N, Braiteh F, Raez L, Erlich R, Ou SI, Mohamed M, Ross JS, **Stephens PJ**, Ali SM, Miller VA. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.*Clin Cancer Res*. 2016 Mar 1.

Ross JS, Gay LM, Nozad S, Wang K, Ali SM, Boguniewicz A, Khaira D, Johnson A, Elvin JA, Vergilio JA, Suh J, Miller VA, **Stephens PJ.** Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. *Breast Cancer Res Treat.* 2016 Jan; 155(2):405-13